多西紫杉醇联合顺铂治疗37例晚期非小细胞肺癌临床分析

Clinical analysis on combined docetaxel and cisplatin for advanced non-small-cell lung cancer in 37 cases

目的观察多西紫杉醇联合顺铂治疗晚期非小细胞肺癌的疗效及不良反应。方法37例经病理和(或)细胞学证实为晚期非小细胞肺癌患者,予多西紫杉醇75mg/m2,静滴60mind1;DDP25～30mg/m2,静滴,d1-3。21d为1周期,2周期为1个疗程。结果全组无CR病例,PR16例,SD17例,PD4例,总有效率43.2%,中位生存期11.3个月,1年生存率40.5%。不良反应:主要以骨髓抑制及消化道反应。结论多西紫杉醇联合顺铂治疗晚期非小细胞肺癌的疗效较好,不良反应可耐受。

Objective To observe the efficiency and toxicity of the combination of docetaxel and cisplatin in the treatment of advanced non-small-cell lung cancer. Methods Thirty-seven patients with advanced non-small-cell lung cancer confirmed by tissue pathology and/or cytopathology, were administered with docetaxel 75mg/m^2 , intravenous dl, cisplantin 25 -- 30mg/m^2 , intravenous d1-d3,every 21d was one cycle and two cycles were one course of treatment. Results There were no case of CR, 16 cases of PR, 17 cases of SD and 4 cases of PD. The total response rate was 43.2% ,the median survival time 11.3 months,one year survival rate 40.5%. The major side effect and toxicity were bone marrow suppression and digestive reactions. Conclusion The combination of docetaxel and cisplatin has a good response in the treatment of advanced non-small-cell lung cancer, the side effect and toxicity are tolerable.